Athar Ansari, MD
Interventional Cardiology · El Centro, CANPI 1477612877
Payments from drug & device makers
Across 556 payments — averaging $79.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Catheter Precision, Inc. FKA Ra Medical Systems, Inc.$37K
- Merck$782
- Medtronic$740
- Biotronik Inc.$729
- Bard Peripheral Vascular, Inc.$565
- Amgen$558
- plus $4K from 32 others
Across 1 payment — averaging $2298.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Catheter Precision, Inc. FKA Ra Medical Systems, Inc.$2K
What the payments were for
- Consulting fees$11,22525%
- Travel & lodging$24,18355%
- Food & beverage$8,57519%
- Education$830%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Catheter Precision, Inc. FKA Ra Medical Systems, Inc. | 119 | $36,681 |
| Merck | 33 | $782 |
| Medtronic(2 entities) | 49 | $740 |
| Biotronik Inc. | 47 | $729 |
| Bard Peripheral Vascular, Inc. | 45 | $565 |
| Amgen | 39 | $558 |
| Johnson & Johnson | 43 | $523 |
| Abbott | 29 | $498 |
| Boston Scientific | 24 | $492 |
| Cardiva Medical, Inc. | 25 | $361 |
| Bayer | 10 | $262 |
| Novartis | 14 | $235 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $232 |
| Amarin Pharma, Inc. | 11 | $218 |
| E.r. Squibb & Sons, L.L.C. | 8 | $151 |
| Acist Medical Systems, Inc. | 3 | $131 |
| Boehringer Ingelheim | 5 | $106 |
| Edwards Lifesciences | 2 | $101 |
| Lexicon Pharmaceuticals, Inc. | 4 | $84 |
| Pfizer | 5 | $77 |
| Gilead | 4 | $62 |
| Novo Nordisk | 3 | $58 |
| Terumo Medical Corporation | 2 | $52 |
| Heartflow, Inc. | 1 | $41 |
| AstraZeneca | 2 | $37 |
| Cardiovascular Systems Inc. | 2 | $36 |
| BD | 2 | $32 |
| Baxter Healthcare | 1 | $31 |
| Vifor Pharma, Inc. | 2 | $27 |
| Reflow Medical Inc | 1 | $25 |
| Actelion Pharmaceuticals US, Inc. | 3 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $19 |
| Irhythm Technologies, Inc. | 1 | $19 |
| Teleflex LLC | 1 | $18 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| AbbVie | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DABRA$24,074
- DABRA 101 Catheter$7,725
- COREVALVE EVOLUT R$162
- Kerendia$125
- LifeVest$100
How this compares
$44,067 in reported general payments places this provider in the 75th percentile of 585 interventional cardiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 711 | $689,303 |
| EliquisApixaban | 427 | $372,827 |
| XareltoRivaroxaban | 214 | $170,430 |
| Repatha SureclickEvolocumab | 183 | $115,264 |
| Praluent PenAlirocumab | 111 | $64,307 |
| BrilintaTicagrelor | 91 | $50,947 |
| Repatha SyringeEvolocumab | 46 | $35,378 |
| MultaqDronedarone Hcl | 27 | $34,244 |
| VerquvoVericiguat | 26 | $26,611 |
| JanuviaSitagliptin Phosphate | 25 | $26,254 |
| JardianceEmpagliflozin | 25 | $24,615 |
| FarxigaDapagliflozin Propanediol | 20 | $18,286 |
| VascepaIcosapent Ethyl | 31 | $17,362 |
| OzempicSemaglutide | 16 | $13,709 |
| Icosapent Ethyl | 51 | $12,241 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $235 | $689,303711 claims |
| PfizerEliquis | $77 | $372,827427 claims |
| Johnson & JohnsonXarelto | $523 | $170,430214 claims |
| AstraZenecaBrilinta, Farxiga | $37 | $69,233111 claims |
| MerckVerquvo, Januvia | $782 | $52,86651 claims |
| Sanofi-aventis U.S. LLCMultaq | $20 | $34,24427 claims |
| Boehringer IngelheimJardiance | $106 | $24,61525 claims |
| Novo NordiskOzempic | $58 | $13,70916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 585 interventional cardiology providers in California.
Other interventional cardiology in El Centro
- Rajendra MakkarWest Hollywood$16.6M
- Fahed BitarCovina$9.9M
- Rahul SharmaStanford$6.6M
- Matthew Pricela Jolla$5.8M
- David LeeStanford$5.7M
- Saibal KarThousand Oaks$5.4M
- Mehrdad ArianiNorthridge$5M
- Frederick St GoarMountain View$4.2M
- Sammy ElmariahSan Francisco$4.2M
- William FearonStanford$3.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.